The wider loss is the cost of two pivotal programs moving at once, with R&D more than doubling to $34.5 million on the Mantle acquisition and an LX2006 milestone. What actually moves this $236 million biotech is the gene therapy data released alongside it: an 80% mean reduction in non-sustained ventricular tachycardia in high-dose LX2020 patients, with the FDA open to that endpoint for a pivotal study starting in 2H 2027.
Lexeo Therapeutics Inc
LXEO at a Glance
- Market cap
- $235.6M
- EPS (TTM)
- $-1.02
- 52-week range
- $3 – $11
- Street target
- $20.67
- Next report
- Nov 18, 2026
Headquartered in New York, NY Fiscal year ends December NASDAQ: LXEO lexeotx.com
About Lexeo Therapeutics
Lexeo Therapeutics is a clinical-stage, pre-revenue biotechnology company developing therapies that address the underlying genetic causes of cardiovascular and neurological diseases.
Its two clinical-stage AAV gene therapies use the cardiac-tropic AAVrh.10 capsid:
- LX2006 targets Friedreich ataxia cardiomyopathy. It is in the SUNRISE-FA 2 pivotal study, initiated in June 2026, with topline data expected in 2H 2027 and a potential BLA under accelerated approval in 1H 2028.
- LX2020 targets PKP2 arrhythmogenic cardiomyopathy, which affects about 60,000 people in the U.S. It is in the HEROIC-PKP2 Phase I/II trial and holds RMAT, Orphan Drug and Fast Track designations. A pivotal study is planned for 2H 2027.
Following its September 2026 acquisition of Mantle Therapeutics, Lexeo runs a multimodal Friedreich ataxia platform:
- LX3010, a clinical-stage oral combination.
- LX3030, an oral HDAC inhibitor.
- LX3050, a TfR1-targeted frataxin-replacement fusion protein.
- LX3070, a TfR1-targeted antisense oligonucleotide.
The pipeline also includes preclinical cardiac gene therapies LX2021 (desmoplakin cardiomyopathy) and LX2022 (TNNI3 hypertrophic cardiomyopathy), plus Alzheimer's APOE2-based gene therapy programs (LX1001, LX1021, LX1020). Lexeo has a research collaboration with Johnson & Johnson on cardiac AAV delivery routes. It uses an optimized Sf9 baculovirus manufacturing platform and retains global rights across all programs. Updated
Frequently Asked Questions
What does Lexeo Therapeutics do?
Lexeo Therapeutics is a clinical-stage, pre-revenue biotechnology company developing therapies that address the underlying genetic causes of cardiovascular and neurological diseases. Its two clinical-stage AAV gene therapies use the cardiac-tropic AAVrh.10 capsid: - LX2006 targets Friedreich ataxia cardiomyopathy.
What is the LXEO stock price target?
The Wall Street consensus 12-month price target for LXEO is $20.67.